AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28421334 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring
Number of subjects: 889
Study 28421634 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation
Number of subjects: 7
Study 28422025 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged glucocorticoid treatment
Number of subjects: 0
Study 28422025 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28422442 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgenotype C1
Number of subjects: 0
Study 28422442 — intervention group
Group type: COMPARATOR
Intervention: Subgenotype B2 and C2
Number of subjects: 0
Study 28422536 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 214
Study 28422536 — intervention group
Group type: EXPERIMENTAL
Intervention: Group/commercial support
Number of subjects: 214
Study 28422536 — intervention group
Group type: EXPERIMENTAL
Intervention: Other behavioral strategies
Number of subjects: 214
Study 28422631 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional assessments
Number of subjects: 12
Study 28422631 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality assessment
Number of subjects: 12
Study 28422631 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil assessments
Number of subjects: 12
Study 28422751 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccine (DC vaccine) injected intradermally in high doses over 2 years
Number of subjects: 53
Study 28422751 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccine (DC vaccine)
Number of subjects: 53
Study 28422751 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab treatment
Number of subjects: 53
Study 28422758 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 80 mg daily plus cetuximab 200 mg/m2 loading dose, followed by 150 mg/m2 every week
Number of subjects: 27
Study 28422836 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 30
Study 28423296 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag plus standard immunosuppressive therapy (cohort 1: day 14 to 6 months)
Number of subjects: 92
Study 28423296 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag plus standard immunosuppressive therapy (cohort 2: day 14 to 3 months)
Number of subjects: 92
Study 28423296 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag plus standard immunosuppressive therapy (cohort 3: day 1 to 6 months)
Number of subjects: 92
Study 28423296 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag plus standard immunosuppressive therapy (combined cohorts)
Number of subjects: 92
Study 28423296 — intervention group
Group type: COMPARATOR
Intervention: Historical cohort (no eltrombopag)
Number of subjects: 92
Study 28423296 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag plus standard immunosuppressive therapy
Number of subjects: 92
Study 28424071 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (400 mg per day)
Number of subjects: 27
Study 28424085 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with antibiotics
Number of subjects: 0
Study 28424085 — intervention group
Group type: EXPERIMENTAL
Intervention: Less drug pressure
Number of subjects: 0
Study 28424085 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring bacterial population dynamics
Number of subjects: 0
Study 28424092 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency of fish food consumption
Number of subjects: 1092
Study 28424092 — intervention group
Group type: COMPARATOR
Intervention: Low frequency of fish food consumption
Number of subjects: 1092
Study 28424162 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 25
Study 28424891 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib plus Erlotinib (100 mg QD)
Number of subjects: 80
Study 28424891 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib plus Temsirolimus (25 mg once weekly)
Number of subjects: 80
Study 28424889 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly docetaxel with capecitabine
Number of subjects: 53
Study 28425349 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI-FLAIR mismatch
Number of subjects: 699
Study 28425349 — intervention group
Group type: COMPARATOR
Intervention: No DWI-FLAIR mismatch
Number of subjects: 699
Study 28425755 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration with percutaneous coronary intervention
Number of subjects: 1641
Study 28425755 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention alone
Number of subjects: 1641
Study 28426120 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaratumab 20 mg/kg intravenously every 14 days until disease progression, death, or intolerable toxicity.
Number of subjects: 30
Study 28426811 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (if PCT <0.5 ng/ml)
Number of subjects: 253
Study 28426811 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (if PCT ≥0.5 ng/ml)
Number of subjects: 253
Study 28426811 — intervention group
Group type: COMPARATOR
Intervention: Historical standard-of-care control group
Number of subjects: 253
Study 28427285 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estradiol/progesterone
Number of subjects: 22
Study 28427285 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide (GnRH agonist)
Number of subjects: 22
Study 28427285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28427285 — intervention group
Group type: EXPERIMENTAL
Intervention: Second and third months of estradiol/progesterone
Number of subjects: 22
Study 28427380 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones and Creating Futures intervention
Number of subjects: 0
Study 28427380 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28427434 — intervention group
Group type: EXPERIMENTAL
Intervention: AdCD40L gene therapy
Number of subjects: 15
Study 28427585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 28427585 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 28427598 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)-based area oversizing
Number of subjects: 835
Study 28427598 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)-based perimeter oversizing
Number of subjects: 835
Study 28427598 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 transcatheter heart valve (THV) implantation
Number of subjects: 835
Study 28427826 — intervention group
Group type: COMPARATOR
Intervention: Suvorexant 30 mg (N=319)
Number of subjects: 627
Study 28427826 — intervention group
Group type: COMPARATOR
Intervention: Suvorexant 15 mg (N=202)
Number of subjects: 627
Study 28427826 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=469)
Number of subjects: 627
Study 28427826 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 30 mg
Number of subjects: 627
Study 28427826 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 15 mg
Number of subjects: 627
Study 28427826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 627
Study 28428158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health intervention (smartphone app) for medication and symptom management
Number of subjects: 0
Study 28428165 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (DREAM-GLOBAL) for hypertension management
Number of subjects: 0
Study 28428165 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (DREAM-GLOBAL)
Number of subjects: 0
Study 28428183 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cephalic presentation
Number of subjects: 0
Study 28428183 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple births
Number of subjects: 0
Study 28428183 — intervention group
Group type: COMPARATOR
Intervention: Singleton births
Number of subjects: 0
Study 28428183 — intervention group
Group type: COMPARATOR
Intervention: Cephalic presentation
Number of subjects: 0
Study 28428225 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin treatment for 2 days
Number of subjects: 30
Study 28428225 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin treatment for 14 days
Number of subjects: 30
Study 28428322 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII)
Number of subjects: 590
Study 28428322 — intervention group
Group type: COMPARATOR
Intervention: Multiple Daily Insulin Injections (MDI)
Number of subjects: 590
Study 28428348 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT (Direct Aspiration First Pass Technique)
Number of subjects: 347
Study 28428882 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy treated mice
Number of subjects: 0
Study 28428882 — intervention group
Group type: COMPARATOR
Intervention: Control mice
Number of subjects: 0
Study 28428882 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing systemic high dose IL-2
Number of subjects: 0
Study 28428884 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg twice daily and ipilimumab 3 mg/kg every 3 weeks
Number of subjects: 35
Study 28429083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully implantable treprostinil infusion pump
Number of subjects: 30
Study 28429860 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide with biguanide
Number of subjects: 294
Study 28429860 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide with thiazolidinedione
Number of subjects: 294
Study 28429860 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide with alpha-glucosidase
Number of subjects: 294
Study 28429860 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide with glinide
Number of subjects: 294
Study 28431167 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Number of subjects: 87
Study 28431171 — intervention group
Group type: EXPERIMENTAL
Intervention: Monozygotic twins
Number of subjects: 91
Study 28431171 — intervention group
Group type: COMPARATOR
Intervention: Dizygotic twins
Number of subjects: 91
Study 28431171 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 91
Study 28431485 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab
Number of subjects: 123
Study 28431564 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch
Number of subjects: 412
Study 28431579 — intervention group
Group type: EXPERIMENTAL
Intervention: TSN program implementation
Number of subjects: 0
Study 28431579 — intervention group
Group type: COMPARATOR
Intervention: Comparison territories (control)
Number of subjects: 0
Study 28431614 — intervention group
Group type: EXPERIMENTAL
Intervention: Permeability surface area product (PS), cerebral blood flow (CBF), and cerebral blood volume (CBV) calculated within the ischemic territory.
Number of subjects: 200
Study 28431614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral blood volume (CBV) threshold of 1.7ml/100g.
Number of subjects: 200
Study 28431614 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete ischemic region analysis of permeability surface area (PS).
Number of subjects: 200
Study 28431614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean PS values for midline shift prediction.
Number of subjects: 200
Study 28431663 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib
Number of subjects: 0
Study 28431663 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28432209 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum sampling for detection of bacteria and viruses
Number of subjects: 0
Study 28432209 — intervention group
Group type: EXPERIMENTAL
Intervention: NTHi airway infection
Number of subjects: 0
Study 28432444 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 35
Study 28432444 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 35
Study 28432444 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS) and Computed tomography (CT)
Number of subjects: 35
Study 28432612 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz electrical stimulus at the wrist, increasing current intensity from 0-30 mA (5 mA increments), applied for three minutes at each level.
Number of subjects: 23
Study 28432612 — intervention group
Group type: EXPERIMENTAL
Intervention: ANI monitoring before and after electrical stimulation.
Number of subjects: 23
Study 28432691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor 15 mg twice daily over 4 days
Number of subjects: 28
Study 28432691 — intervention group
Group type: COMPARATOR
Intervention: Cefadroxil 500 mg for 1 day
Number of subjects: 28
Study 28432691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 500 mg and Tenapanor 15 mg on day 5
Number of subjects: 28
Study 28433206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 495
Study 28433206 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 495
Study 28433498 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400mg (AOM 400)
Number of subjects: 88
Study 28433500 — intervention group
Group type: EXPERIMENTAL
Intervention: MATRICS Consensus Cognitive Battery (MCCB) administered twice prior to treatment initiation in 1908 patients.
Number of subjects: 2616
Study 28433924 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-mg deuterium-labeled methyl d9-TMAO (d9-TMAO)
Number of subjects: 40
Study 28434275 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional home-based palliative care program
Number of subjects: 84
Study 28434275 — intervention group
Group type: COMPARATOR
Intervention: Customary palliative care service
Number of subjects: 84
Study 28434648 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks (dose-expansion phase)
Number of subjects: 262
Study 28434648 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (dose-escalation phase)
Number of subjects: 262
Study 28434660 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with reduced-dose radiation (54 Gy for 24 patients with complete or partial responses; 60 Gy for 20 patients with less than partial responses)
Number of subjects: 44
Study 28434660 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (175 mg/m)
Number of subjects: 44
Study 28434660 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with reduced-dose radiation
Number of subjects: 44
Study 28434702 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan, 10 mg/kg/d in chow
Number of subjects: 0
Study 28434702 — intervention group
Group type: COMPARATOR
Intervention: GW9662, 3 mg/kg/d through oral gavage
Number of subjects: 0
Study 28434702 — intervention group
Group type: COMPARATOR
Intervention: AT1a KO mice (no treatment mentioned)
Number of subjects: 0
Study 28434819 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Test of the Hemiparetic Upper Extremity (FTHUE)
Number of subjects: 109
Study 28434944 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV (3×10^6, 1×10^7, and 2×10^7 PFU)
Number of subjects: 30
Study 28434944 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV (highest dose cohort)
Number of subjects: 30
Study 28436937 — intervention group
Group type: EXPERIMENTAL
Intervention: BPS804 (5, 10, and 20 mg/kg) administered intravenously on days 1, 15, and 29
Number of subjects: 8
Study 28436937 — intervention group
Group type: EXPERIMENTAL
Intervention: BPS804
Number of subjects: 8
Study 28437260 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute post-surgical neuropathic pain assessed using DN4 questionnaire (score ≥ 4/10) on day 0 or day 2.
Number of subjects: 593
Study 28437260 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent post-surgical neuropathic pain (PPSNP) assessed using DN2 questionnaire (score ≥ 3/7) at 2 months after surgery.
Number of subjects: 593
Study 28437260 — intervention group
Group type: EXPERIMENTAL
Intervention: DN4 score at least 4/10 on day 0 or day 2 as a risk factor for PPSNP.
Number of subjects: 593
Study 28437326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fish oil-based lipid emulsion (FishLE) at a dosage of 1 g·kg·day until resolution of direct hyperbilirubinemia or return of enteral nutrition.
Number of subjects: 13
Study 28437326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fish oil-based lipid emulsion (FishLE)
Number of subjects: 13
Study 28437326 — intervention group
Group type: COMPARATOR
Intervention: Control group (GA-matched controls)
Number of subjects: 13
Study 28437380 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater aerobic capacity
Number of subjects: 160
Study 28437380 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activity
Number of subjects: 160
Study 28437380 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the DASH diet
Number of subjects: 160
Study 28437380 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater high-sensitivity C-reactive protein
Number of subjects: 160
Study 28437380 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham Stroke Risk Profile
Number of subjects: 160
Study 28437488 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg single oral dose in c.662AG subjects
Number of subjects: 20
Study 28437668 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine XR
Number of subjects: 98
Study 28438076 — intervention group
Group type: EXPERIMENTAL
Intervention: Work and Social Engagement (WSAS)
Number of subjects: 185
Study 28438076 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive Symptoms
Number of subjects: 185
Study 28438076 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Rankin Scale (mRS)
Number of subjects: 185
Study 28438076 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 185
Study 28438090 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite mesh with polypropylene and expanded polytetrafluoroethylene (Intramesh)
Number of subjects: 90
Study 28438154 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted gene co-expression network analysis (WGCNA) applied to peripheral blood transcriptome.
Number of subjects: 238
Study 28438304 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable Vascular Scaffold (BVS) implantation
Number of subjects: 1505
Study 28438723 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical atrial fibrillation ablation (MISAA)
Number of subjects: 109
Study 28438728 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention (twice daily for 6 months) tailored to participant's stage of behavior change
Number of subjects: 31
Study 28438728 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 31
Study 28438739 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 13909
Study 28438739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13909
Study 28439092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic very-low-energy diet (VLED)
Number of subjects: 31
Study 28439879 — intervention group
Group type: EXPERIMENTAL
Intervention: PD1 inhibition
Number of subjects: 0
Study 28440046 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic-type diet (PD)
Number of subjects: 70
Study 28440046 — intervention group
Group type: COMPARATOR
Intervention: Prudent control diet (CD)
Number of subjects: 70
Study 28440113 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular procedures in diabetics
Number of subjects: 1906
Study 28440113 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular procedures in diabetics with CLI
Number of subjects: 1906
Study 28440113 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular procedures in diabetics with claudication
Number of subjects: 1906
Study 28441027 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Blocker Therapy
Number of subjects: 0
Study 28441027 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28441111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg once every 3 weeks
Number of subjects: 210
Study 28441695 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with type 2 diabetes
Number of subjects: 106
Study 28442212 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater ultrasound therapy
Number of subjects: 48
Study 28442293 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate therapy (active drug against the blood isolate started in the first 5 days after infection)
Number of subjects: 437
Study 28442293 — intervention group
Group type: COMPARATOR
Intervention: Inappropriate therapy
Number of subjects: 437
Study 28442293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (more than one active drug) among those receiving appropriate therapy
Number of subjects: 437
Study 28442293 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy (only one active drug) among those receiving appropriate therapy
Number of subjects: 437
Study 28442293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy in high-mortality-score stratum
Number of subjects: 437
Study 28442293 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy in high-mortality-score stratum
Number of subjects: 437
Study 28442293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy in low-mortality-score stratum
Number of subjects: 437
Study 28442293 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy in low-mortality-score stratum
Number of subjects: 437
Study 28442451 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message survey
Number of subjects: 491
Study 28442451 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone UTI symptom diary app
Number of subjects: 491
Study 28442451 — intervention group
Group type: EXPERIMENTAL
Intervention: Online survey
Number of subjects: 491
Study 28442453 — intervention group
Group type: EXPERIMENTAL
Intervention: Clickotine app
Number of subjects: 416
Study 28443046 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving Behavior Intervention (CBI) - six-session intervention
Number of subjects: 63